Specifically, mementor developed somnio, Germany’s only approved Digital Health Application (DiGA) for clinically relevant insomnia. It is also Germany’s only DiGA that is reimbursed by statutory insurances in Germany.
Clinically relevant insomnia impacts roughly one in 10 people in Germany (and nearly three in 10 people there, as well). However, only a small portion of those affected by clinically relevant insomnia receive the cognitive behavioral therapy for insomnia (CBT-I) recommended by Germany’s S3 guideline.
Available today in Germany via "app on prescription," somnio has been shown in two randomized controlled trials to provide a sustained improvement in users’ sleep after two and 12 months.
"mementor is an ideal fit for ResMed Germany and, more important, millions of people across Germany who want to improve their sleep and overall health," said Katrin Pucknat, president of ResMed Germany. "The founders have identified a large and neglected area of healthy sleep with an opportunity to help millions of people solve their chronic sleep issue with an easy-to-use digital at-home solution. We look forward to working with the team at mementor to help even more people in Germany achieve good, healthy sleep."
ResMed will integrate mementor into its business in Germany as a separate business segment which will serve as a platform for further developments in the field of digital health. That business segment will be co-led by mementor co-founder and CEO Dr. Noah Lorenz and Katherina Jekerle, who was previously ResMed Germany’s senior marketing director and member of the German leadership team.
"Joining forces with ResMed brings us a big step closer to our vision of helping people get a good and healthy night’s sleep," Lorenz said. "I am excited to have found a perfect fit in ResMed, with whom we can work together to give more people access to somnio and develop further digital solutions. We look forward to joining the global ResMed family."
"I am very much looking forward to working with the mementor team on further innovating digital solutions and helping more people suffering from insomnia with a digital therapy approach," said Jekerle. "In doing so, we at ResMed Germany are committed to maintaining the start-up agility and creativity of the teams and support the brand as it continues to grow."
The financial terms of the transaction were not disclosed.